TY -的T1 -在线儿童哮喘管理是具有成本效益的JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.01413 -2017欧元六世- 50 - 4 SP - 1701413 AU - van den Wijngaart,劳拉s . AU - Kievit Wietske盟——Roukema震动AU -》,Annemie L.M.盟——这,玛丽安·l . AU - Hugen辛迪交流AU -尼尔,Laetitia E.M. AU - Sprij, Arwen J. AU - Rikkers-Mutsaerts, Eleonora R.V.M. AU - Rottier, Bart L. AU - Verhaak, Chris M. AU - Pijnenburg, Mariëlle W. AU - Merkus，Peter J.F.M. Y1 - 2017/10/01 UR - //www.qdcxjkg.com/content/50/4/1701413.abstract N2 - eHealth干预措施已被提议作为一种有吸引力的方法来改善健康结果和降低医疗成本[1-3]。然而，电子健康干预的发展与高成本相关，这种投资需要通过提高临床效果和相关成本节约来平衡。不幸的是，关于电子健康在改善健康方面的有效性的确凿证据仍然有限[2-5]，关于成本效益的证据也是如此。这导致了对电子健康有效性的不确定性，并构成了在日常实践中成功实施的障碍[6,7]。因此，有必要评估其有效性和成本效益，以说服同事和决策者相信其附加价值。儿童哮喘在线管理可以(部分)替代常规门诊，而且成本效益好http://ow.ly/oabk30f7SrePijnenburg Marielle;Verhaak, Chris设计了这项研究并获得了资金。 van den Wijngaart, Lara; Roukema, Jolt; Boehmer, Annemie; Brouwer, Marianne; Verhaak, Chris; Niers, Laetitia; Sprij, Arwen; Rikkers-Mutsaerts, Eleonora; Rottier, Bart; Pijnenburg, Mariëlle; Merkus, Peter all participated as investigators, recruited patients and performed treatments. van den Wijngaart, Lara carried out the analyses. Kievit, Wietske conducted the cost-effectiveness analysis. van den Wijngaart, Lara; Kievit, Wietske; Roukema, Jolt; Merkus, Peter operated as the writing committee and drafted the manuscript until it reached its final form. All authors commented on the manuscript and its revisions. Merkus, Peter is the guarantor of the study. Ethical approval: This study was approved by all local ethics committees. All participants provided written informed consent. Data sharing: Patient-level data are available on reasonable request from the corresponding author. Patient consent was not obtained but the data presented are anonymised and risk of identification is absent. Transparency declaration: The lead author affirms that this manuscript is an honest, accurate and transparent account of the study being reported, that no important aspects of the study have been omitted, and that any discrepancies from the study as planned (and, if relevant, registered) have been explained. Prior presentations: Results of this randomised controlled trial were presented at the Congress of the European Respiratory Society (Amsterdam, 2015). Results of the cost-effectiveness analysis were presented at the Congress of International Paediatric Pulmonology (Naples, 2016). Thanks: We are grateful to all the participating children and parents for their contribution to this study, as well as collaborating paediatricians and Sintnicolaas, Coosje (Radboud University Medical Centre, Amalia Children’s Hospital, Department of Paediatric Pulmonology, Nijmegen, The Netherlands); Stevens, Petra (Canisius Wilhelmina Hospital, Department of Paediatrics, Nijmegen, The Netherlands); Verwaal, Mariël (Maasstad Hospital, Department of Paediatrics, Rotterdam, The Netherlands); Bolder, Carola (Maxima Medical Centre, Department of Paediatrics, Veldhoven, The Netherlands); Winters, Ans (Leiden University Medical Centre, Department of Paediatric Pulmonology, Leiden, The Netherlands); Mulder, Ineke and van Baak, Christine (both Haga Hospital, Juliana Children’s Hospital, Department of Paediatric Pulmonology, The Hague, The Netherlands); Spierings, Magda and Hiddinga, Jantine (both Erasmus Medical Centre, Sophia Children’s Hospital and Kinderhaven/Havenziekenhuis, Department of Paediatric Pulmonology, Rotterdam, The Netherlands) for their enthusiasm and their efforts in recruiting and monitoring the patients. We acknowledge Hop, Wim (Erasmus Medical Centre, Department of Biostatistics, Rotterdam, The Netherlands) and Moll, Henriëtte (Erasmus Medical Centre, Sophia Children’s Hospital, Department of Paediatrics, Rotterdam, The Netherlands) for performing the interim safety analysis and also commemorate van Gent, Rene (Maxima Medical Centre, Department of Paediatrics, Veldhoven, The Netherlands) and thank him for his contributions to this study. ER -